Total Revenues

Bristol-Myers Squibb·Products & Services·27 segments·Rolls up to Total Revenue

Breakdown

Segment	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Eliquis	$3.42B	$3B	$3.2B	$3.57B	$3.68B	$3.75B	$3.45B	$4.14B
Opdivo	$2.39B	$2.36B	$2.48B	$2.27B	$2.56B	$2.53B	$2.69B	$2.15B
Orencia	$948M	$936M	$1B	$770M	$963M	$964M	$1.01B	$818M
Yervoy	$630M	$642M	$675M	$624M	$728M	$739M	$810M	$651M
Other Growth products	$348M	$443M	$527M	$507M	$470M	$514M	$536M	$581M
Reblozyl	$425M	$447M	$547M	$478M	$568M	$615M	$666M	$555M
Pomalyst/Imnovid	$959M	$898M	$823M	$658M	$708M	$675M	$692M	$513M
Breyanzi	$153M	$224M	$263M	$263M	$344M	$359M	$392M	$411M
Revlimid	$1.35B	$1.41B	$1.34B	$936M	$838M	$575M	$602M	$349M
Camzyos	$139M	$156M	$223M	$159M	$260M	$296M	$354M	$314M
Opdualag	$235M	$233M	$254M	$252M	$284M	$299M	$350M	$295M
Opdivo Qvantig	—	—	—	$9M	$30M	$67M	$133M	$163M
Other Legacy products	$222M	$225M	$250M	$199M	$223M	$177M	$199M	$156M
Zeposia	$151M	$147M	$158M	$107M	$150M	$161M	$159M	$118M
Sprycel	$424M	$290M	$198M	$175M	$120M	$119M	$80M	$73M
Sotyktu	$53M	$66M	$83M	$55M	$70M	$80M	$85M	$69M
Cobenfy	—	—	—	$27M	$35M	$43M	$50M	$56M
Krazati	$32M	$34M	$39M	$48M	$48M	$53M	$56M	$50M
Abraxane	$231M	$253M	$174M	$105M	$105M	$74M	$84M	$50M
Other revenue	—	—	—	—	—	—	—	-$15M
Total	$12.2B	$11.89B	$12.34B	$11.2B	$12.27B	$12.22B	$12.5B	$11.49B